criticalBAMF Healthvia ChatGPTFeb 27
“Expanded FDA indication — March 28, 2025 Now also indicated for adult patients with PSMA‑positive mCRPC who: - Have been treated with ARPI therapy, and - Are considered appropriate to delay taxane”
Reality: The AI is hallucinating a future FDA approval date (March 2025) and an expanded indication that does not exist in the verified claims. This presents a serious regulatory risk by claiming a drug can be used in a pre-chemotherapy setting before such an indication is officially verified or approved.
criticalBAMF Healthvia GeminiFeb 27
“* **Pre-Chemotherapy (Taxane-naïve):** As of **March 2025**, the FDA expanded the indication for Pluvicto to include patients with PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibition (ARPI) but have **not yet received chemotherapy** [bamfhealth”
Reality: The AI is hallucinating a future date (March 2025) and a corresponding expanded FDA approval for Pluvicto in pre-chemotherapy settings. Current FDA indications are limited to post-chemotherapy and post-ARPI treatment. Claiming an expanded indication provides false medical guidance and creates significant regulatory and legal liability for a healthcare brand.
criticalBAMF Healthvia ChatGPTFeb 27
“Additionally, in a May 12, 2025 update, BAMF Health announced that patients can now receive Pluvicto **before chemotherapy**, reflecting the March 2025 FDA expansion ([bamfhealth”
Reality: The AI is hallucinating future dates (2025) and a non-existent FDA expansion for Pluvicto. As of current real-world data, Pluvicto's FDA-approved label still requires patients to have been treated with both an ARPI and a taxane-based chemotherapy. Claiming an expanded pre-chemotherapy indication before it exists is a significant medical and regulatory inaccuracy.
criticalUwillvia GeminiFeb 26
“* **Emergency Limitations:** Uwill's Terms of Service (last updated June 2022) explicitly state that the service is not for emergency medical needs and directs users to traditional emergency services (911) for immediate life-threatening crises [uwill”
Reality: This directly contradicts the verified claim regarding Uhelp, which provides 24/7/365 crisis support with licensed trauma-trained therapists reached within 30 seconds. Telling a user in crisis that the service is 'not for emergency needs' could result in life-threatening delays by discouraging the use of the intended crisis tool.
criticalAtropos Healthvia ChatGPTFeb 26
“- Compliance claims including **HIPAA, SOC 2, ISO 27001, HITECH, GDPR**, and certifications such as FDA 510(k) and CE/MDR ([healthaidb”
Reality: Claiming FDA 510(k) clearance and CE/MDR certification is a high-risk regulatory assertion. Atropos Health provides real-world evidence and analytics, not a cleared medical device. Falsely claiming FDA clearance or CE marking creates significant legal and regulatory risk.